Related Experiment Video
Updated: May 12, 2026
07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Guillain-barré syndrome
Mazen M Dimachkie1, Richard J Barohn
1Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Blvd., Mail Stop 2012, Kansas City, KS, 66160, USA, mdimachkie@kumc.edu.
Current Treatment Options in Neurology
|April 12, 2013
Summary
Guillain-Barré syndrome (GBS) encompasses acute inflammatory polyneuropathies. Early diagnosis and treatment of these autoimmune neuromuscular disorders are improving patient outcomes.
Area of Science:
- Neurology
- Immunology
- Neuromuscular Disorders
Background:
- Acute inflammatory polyneuropathies, collectively known as Guillain-Barré syndrome (GBS), are significant neuromuscular disorders.
- Autoimmune processes in GBS can affect myelin or axons at various nerve locations, presenting diverse patterns.
- Advances in understanding GBS pathogenesis, diagnosis, and management offer improved identification and treatment opportunities.
Purpose of the Study:
- To review the distinctive clinical, laboratory, and electro-diagnostic features of GBS.
- To emphasize clinical characteristics crucial for diagnosing specific GBS conditions.
- To guide the selection of appropriate therapies and determine long-term prognosis.
Main Methods:
- Review of clinical, laboratory, and electro-diagnostic findings in Guillain-Barré syndrome.
- Emphasis on characteristic clinical features for differential diagnosis.
- Correlation of diagnostic findings with therapeutic strategies and prognostic indicators.
Main Results:
- Distinctive clinical, laboratory, and electro-diagnostic features aid in GBS diagnosis.
- Specific clinical characteristics are paramount for accurate diagnosis and therapy selection.
- Understanding these features improves prognosis assessment for GBS patients.
Conclusions:
- Accurate diagnosis of Guillain-Barré syndrome relies on integrated clinical, laboratory, and electro-diagnostic data.
- Tailored therapies for acquired demyelinating neuropathies are available and effective.
- Comprehensive evaluation aids in optimizing patient management and predicting long-term outcomes in GBS.
More Related Videos
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:25Secondary Spinal Cord Injury llI: Pathophysiology
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...